Advertisement
Canada markets open in 8 hours 47 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7323
    +0.0000 (+0.00%)
     

  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     

  • Bitcoin CAD

    87,766.18
    -17.00 (-0.02%)
     

  • CMC Crypto 200

    1,388.36
    +5.79 (+0.42%)
     

  • GOLD FUTURES

    2,348.60
    +6.10 (+0.26%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,772.75
    +205.25 (+1.17%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,962.35
    +333.87 (+0.89%)
     

  • CAD/EUR

    0.6828
    +0.0007 (+0.10%)
     

Gilead to deliver more remdesivir to Germany, Europe from the Fall - WiWo

Reuters
Updated ·1 min read

BERLIN, July 9 (Reuters) - Gilead Sciences Inc plans to make more of its drug remdesivir available for Germany and Europe from the Fall and will decide how much each country gets based on the rate of infection, the drugmaker's Germany boss told a German magazine.

Bettina Bauer, German managing director of Gilead, told WirtschaftsWoche the U.S. drugmaker can increase its worldwide monthly production from currently 190,000 treatment cycles to two million treatment cycles in December.

Remdesivir is currently the only drug granted a conditional marketing authorisation by the EU for its use in COVID-19 patients.

Bauer said she was in talks with the German government about increasing supply.

(Reporting by Caroline Copley Editing by Riham Alkousaa)